# Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients

> **NCT04673162** · PHASE3 · COMPLETED · sponsor: **Azienda USL Reggio Emilia - IRCCS** · enrollment: 260 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Methylprednisolone, Placebo

## Key facts

- **NCT ID:** NCT04673162
- **Lead sponsor:** Azienda USL Reggio Emilia - IRCCS
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-17
- **Primary completion:** 2021-04-21
- **Final completion:** 2021-07-12
- **Target enrollment:** 260 (ACTUAL)
- **Last updated:** 2022-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673162, "Evaluation of the Efficacy of High Doses of Methylprednisolone in SARS-CoV2 ( COVID-19) Pneumonia Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04673162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*